The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | PACIFIC: Brentuximab vedotin in mediastinal DLBCL
Jason Westin, MD, FACP, University of Texas MD Anderson Center, Houston, TX, describes the trial design of the Phase II PACIFIC trial (NCT04745949) of brentuximab vedotin, an antibody-drug conjugate (ADC), in patients with stage I-IV primary mediastinal diffuse large B-cell lymphoma (DLBCL). The trial aims to evaluate immunotherapy in the frontline setting as an alternative to chemotherapy in patients with mediastinal DLBCL, which will reduce the toxicity experienced by patients. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
